Jump to content

Renal cell carcinoma: Revision history


For any version listed below, click on its date to view it. For more help, see Help:Page history and Help:Edit summary. (cur) = difference from current version, (prev) = difference from preceding version, m = minor edit, → = section edit, ← = automatic edit summary

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

11 July 2024

  • curprev 00:5500:55, 11 July 2024Fuse809 talk contribs 102,252 bytes −1 →‎Targeted drugs: I think paragraph 1 & 2 should be combined, as otherwise it makes it seem like the list below only pertains to drugs that target growth factors, which nivolumab and IL-2 definitely do not do. They are immunotherapies, which the first paragraph pertains to. undo

21 April 2024

21 March 2024

6 February 2024

27 December 2023

21 December 2023

12 December 2023

20 November 2023

25 October 2023

9 October 2023

2 October 2023

20 September 2023

1 September 2023

15 August 2023

8 June 2023

10 May 2023

29 January 2023

15 December 2022

29 September 2022

5 August 2022

11 July 2022

29 June 2022

21 April 2022

5 March 2022

3 March 2022

22 February 2022

17 February 2022

26 January 2022

4 November 2021

27 October 2021

16 September 2021

  • curprev 12:4412:44, 16 September 2021Citation bot talk contribs 100,926 bytes +496 Add: pmc-embargo-date, pmc, pmid, pages, issue, volume, year, doi-access, s2cid, authors 1-3. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by Headbomb | Linked from Wikipedia:WikiProject_Academic_Journals/Journals_cited_by_Wikipedia/Sandbox | #UCB_webform_linked 292/835 undo

18 August 2021

20 June 2021

17 May 2021

13 April 2021

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)